Brown and beige adipose tissues contain thermogenic fat cells that can be activated by β3-adrenergic receptor agonists. In rodents, such drugs both diminish obesity and improve glucose homeostasis. In this issue of the JCI, O’Mara et al. and Finlin and Memetimin et al. report that chronic administration of the approved β3 agonist mirabegron to human subjects was without effect on body weight or fat mass, but improved several measures of glucose homeostasis. Though the mechanisms mediating these metabolic effects are uncertain, the data suggest that β3 agonists could have therapeutic utility in disorders of glucose homeostasis.
Jeffrey S. Flier
Title and authors | Publication | Year |
---|---|---|
Brown adipose tissue activation via UCP1 accelerates cardiac metabolic remodeling and attenuates early hypertrophic and profibrotic signaling in the initial response to pathological stress.
Azariyas Challa, Pablo Vidal, Santosh Maurya, Chandan Maurya, Lisa Baer, Yang Wang, Natasha James, Parth Pardeshi, Matthew Fasano, Andrew Carley, Kristin Stanford, E. Lewandowski |
The FASEB Journal | 2024 |
HDAC11 inhibition triggers bimodal thermogenic pathways to circumvent adipocyte catecholamine resistance
Emma L. Robinson, Rushita Bagchi, Jennifer Major, Bryan Bergman, Jennifer L. Madsuda, Timothy A. McKinsey |
Journal of Clinical Investigation | 2023 |
HDAC11 inhibition triggers bimodal thermogenic pathways to circumvent adipocyte catecholamine resistance
Robinson EL, Bagchi RA, Major JL, Bergman BC, Madsuda JL, McKinsey TA |
2023 | |
Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug
Dąbrowska AM, Dudka J |
Journal of Clinical Medicine | 2023 |
Reversible lysine fatty acylation of an anchoring protein mediates adipocyte adrenergic signaling
R Bagchi, E Robinson, T Hu, J Cao, J Hong, C Tharp, H Qasim, K Gavin, J da Silva, J Major, B McConnell, E Seto, H Lin, T McKinsey |
Proceedings of the National Academy of Sciences | 2022 |
The evolving view of thermogenic fat and its implications in cancer and metabolic diseases.
Yin X, Chen Y, Ruze R, Xu R, Song J, Wang C, Xu Q |
Signal Transduction and Targeted Therapy | 2022 |
Pioglitazone does not synergize with mirabegron to increase beige fat or further improve glucose metabolism
Brian S. Finlin, Hasiyet Memetimin, Beibei Zhu, Amy L Confides, Hemendra J. Vekaria, Riham H. El Khouli, Zachary R. Johnson, Philip M. Westgate, Jianzhong Chen, Andrew J. Morris, Patrick G. Sullivan, Esther E Dupont-Versteegden, Philip A. Kern |
JCI Insight | 2021 |
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
A Angelidi, M Belanger, A Kokkinos, C Koliaki, C Mantzoros |
Endocrine reviews | 2021 |